Predict your next investment

Corporate Venture
ucbventures.com

See what CB Insights has to offer

Investments

17

Portfolio Exits

1

About UCB Ventures

UCB Ventures is UCB's venture arm that specializes in supporting medical companies.

UCB Ventures Headquarter Location

Allée de la Recherche, 60

Brussels, 1070,

Belgium

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest UCB Ventures News

Code Biotherapeutics Raises $75M in Series A

Jun 9, 2022

Back to HomeHATFIELD, PA, Code Biotherapeutics, a biotechnology company, announced its Series A financing of $75 million led by Northpond Ventures.Code Biotherapeutics, a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announced its upsized and oversubscribed Series A financing of $75 million to advance programs to treat and cure rare and prevalent genetic diseases.Northpond Ventures led the financing round with participation from Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors New Enterprise Associates, 4BIO Capital, CureDuchenne Ventures, the JDRF T1D Fund, UPMC Enterprises, and Takeda Ventures. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.

UCB Ventures Investments

17 Investments

UCB Ventures has made 17 investments. Their latest investment was in Code Biotherapeutics as part of their Series A on June 6, 2022.

CBI Logo

UCB Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/7/2022

Series A

Code Biotherapeutics

$75M

Yes

7

2/16/2022

Series A

SpliceBio

$56.81M

Yes

4

9/14/2021

Seed VC - II

Neurava

$0.66M

Yes

2

6/22/2021

Series D - II

Subscribe to see more

$99M

Subscribe to see more

10

4/20/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/7/2022

2/16/2022

9/14/2021

6/22/2021

4/20/2021

Round

Series A

Series A

Seed VC - II

Series D - II

Series A

Company

Code Biotherapeutics

SpliceBio

Neurava

Subscribe to see more

Subscribe to see more

Amount

$75M

$56.81M

$0.66M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

4

2

10

10

UCB Ventures Portfolio Exits

1 Portfolio Exit

UCB Ventures has 1 portfolio exit. Their latest portfolio exit was Syndesi Therapeutics on March 01, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/1/2022

Acquired

$99M

5

Date

3/1/2022

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

5

UCB Ventures Team

1 Team Member

UCB Ventures has 1 team member, including current Senior Director, Emmanuel Lacroix.

Name

Work History

Title

Status

Emmanuel Lacroix

Senior Director

Current

Name

Emmanuel Lacroix

Work History

Title

Senior Director

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.